Beatrice Mantoan

Legnago, 37045, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Metastatic Colorectal Cancer Beyond Third-Line Treatment: Systematic Review and Meta-Analysis of Later-Line Therapies.

Metastatic Colorectal Cancer Beyond Third-Line Treatment: Systematic Review and Meta-Analysis of Later-Line Therapies.

Journal: Journal of clinical medicine

Published: March 10, 2026

Investigating the Impact of Fusobacterium nucleatum on Oxidative Stress, Chemoresistance, and Inflammation in Inflammatory Bowel Disease and Colorectal Cancer: Rationale and Design of a Clinical Trial.

Investigating the Impact of Fusobacterium nucleatum on Oxidative Stress, Chemoresistance, and Inflammation in Inflammatory Bowel Disease and Colorectal Cancer: Rationale and Design of a Clinical Trial.

Journal: International journal of molecular sciences

Published: June 24, 2025

The screening with the liquid biopsy for the rechallenge with anti-epidermal growth factor receptor antibodies in metastatic colorectal cancer A perspective based on pharmacological costs.

The screening with the liquid biopsy for the rechallenge with anti-epidermal growth factor receptor antibodies in metastatic colorectal cancer A perspective based on pharmacological costs.

Journal: Recenti progressi in medicina

Published: August 02, 2023

Cost-Effectiveness of the New Combination Trifluridine/Tipiracil Plus Bevacizumab for the Third-Line Treatment for Metastatic Colorectal Cancer in Italy.

Cost-Effectiveness of the New Combination Trifluridine/Tipiracil Plus Bevacizumab for the Third-Line Treatment for Metastatic Colorectal Cancer in Italy.

Journal: Clinical colorectal cancer

Published: July 05, 2023

Cost-effectiveness of pembrolizumab in first-line for microsatellite-instability-high or mismatch-repair-deficient metastatic colorectal cancerF.

Cost-effectiveness of pembrolizumab in first-line for microsatellite-instability-high or mismatch-repair-deficient metastatic colorectal cancerF.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Published: February 24, 2023

Cost-effectiveness of poly-(ADP-ribose) polymerase (PARP)-inhibitors for the maintenance treatment after responding to first- and second-line chemotherapy in advanced ovarian cancer.

Cost-effectiveness of poly-(ADP-ribose) polymerase (PARP)-inhibitors for the maintenance treatment after responding to first- and second-line chemotherapy in advanced ovarian cancer.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Published: November 07, 2022

Cost-effectiveness of programmed death ligand-1 (PD-L1) blockade in first-line for metastatic gastric/gastroesophageal junction cancer.

Cost-effectiveness of programmed death ligand-1 (PD-L1) blockade in first-line for metastatic gastric/gastroesophageal junction cancer.

Journal: European journal of cancer (Oxford, England : 1990)

Published: August 05, 2022

Whey proteins isolate supplementation in additional to nutritional counseling in cancer patients.

Whey proteins isolate supplementation in additional to nutritional counseling in cancer patients.

Journal: Recenti progressi in medicina

Published: June 27, 2022

Long-term survivors of metastatic colorectal cancer treated with trifluridine/tipiracil.

Long-term survivors of metastatic colorectal cancer treated with trifluridine/tipiracil.

Journal: Recenti progressi in medicina

Published: June 27, 2022

The optimal duration of immune checkpoint inhibitors in non-oncogene addicted non-small cell lung cancer: less is more? An open question.

The optimal duration of immune checkpoint inhibitors in non-oncogene addicted non-small cell lung cancer: less is more? An open question.

Journal: Recenti progressi in medicina

Published: December 20, 2021

Cost-effectiveness of encorafenib plus cetuximab in BRAF V600E-mutated colorectal cancer.

Cost-effectiveness of encorafenib plus cetuximab in BRAF V600E-mutated colorectal cancer.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Published: September 28, 2021

The cost-effectiveness of new first-line therapies approved in advanced hepatocellular carcinoma.

The cost-effectiveness of new first-line therapies approved in advanced hepatocellular carcinoma.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Published: September 28, 2021

Showing 1-12 of 19

Last Updated: 09/26/2026